The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 19, 2018. Its latest SEC filing is a 8-K from May 3, 2019.
10-Q for Q3 FY2018, filed Nov 19, 2018
The sections below describe the company as of the FY2017 annual report.
Develops individualized immunotherapies for cancer and HIV patients using its Arcelis platform.
10-K for FY2017, filed Apr 2, 2018We are an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of…View ↗
Our proprietary Arcelis precision immunotherapy technology platform utilizes biological components from a patient’s own cancer cells or…View ↗
In addition, we are developing AGS-004, our second Arcelis-based product candidate, for the treatment of HIV. We have completed Phase 1 and…View ↗
The NIH and NIAID reimburse research costs as they are incurred and pay for milestones when achieved. Collaborators provide upfront license fees, milestone payments when achieved, and royalties when licensed products are sold.
10-K for FY2017, filed Apr 2, 2018In September 2006, the Company entered into a multi-year research contract with the NIH and NIAID to design, develop and clinically test an…View ↗
The Company recognizes revenue from reimbursements earned in connection with the NIH and NIAID contract as reimbursable costs are incurred.…View ↗
The Company has entered into license agreements with collaborators. The terms of these agreements have included nonrefundable signing and…View ↗
These collaboration agreements are accounted for in accordance with Accounting Standards Update (“ASU”) No. 2009-13, Topic 605 –…View ↗
The Company’s license agreements with Pharmstandard International S.A. (“Pharmstandard”), Green Cross Corp. (“Green Cross”), Medinet Co.…View ↗
The Company’s current license agreements with Pharmstandard, Green Cross, Medinet and Lummy HK provide for, and any future license…View ↗
$1.9M
10-K for FY2017, filed Apr 2, 2018
$1.9M ↗
The NIH and NIAID fund development under a research contract. Pharmaceutical and biotechnology collaborators take licenses to product rights in specific markets, including Pharmstandard, Green Cross, Medinet and Lummy HK.
10-K for FY2017, filed Apr 2, 2018In September 2006, the Company entered into a multi-year research contract with the NIH and NIAID to design, develop and clinically test an…View ↗
We hold all commercial rights to rocapuldencel-T and AGS-004 in all geographies other than rights to rocapuldencel-T in Russia and the…View ↗
We hold exclusive commercial rights to all of our product candidates in all geographies other than rights to rocapuldencel-T in Russia and…View ↗
No. It lost $40.6M in FY2017.
10-K for FY2017, filed Apr 2, 2018
10-K for FY2017, filed Apr 2, 2018
−$62.5MView ↗
10-K for FY2017, filed Apr 2, 2018
−$40.6MView ↗
10-K for FY2017, filed Apr 2, 2018
−$39.1MView ↗
10-Q for Q3 FY2018, filed Nov 19, 2018
−$5MView ↗
8-K, filed May 3, 2019
PwC’s report on the Company’s financial statements as of and for the fiscal year ended December 31, 2017 did not contain any adverse…View ↗
8-K, filed Dec 3, 2018
On November 30, 2018, after considering all strategic alternatives, Argos Therapeutics, Inc., a Delaware corporation (the "Company"), filed…View ↗
8-K, filed Apr 24, 2018
On April 23, 2018, Argos Therapeutics, Inc. (the “Company”) received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) indicating…View ↗
Shrank. Revenue fell 57% in 4 years, from $4.4M in FY2013 to $1.9M in FY2017, about 19% a year.
Competes with Bayer Healthcare Pharmaceuticals, Onyx Pharmaceuticals, Pfizer, Genentech, Novartis Pharmaceuticals, Bristol-Myers Squibb, Exelixis, and Merck
10-K for FY2017, filed Apr 2, 2018Historically, mRCC was treated with chemotherapy, radiation and hormonal therapies, as well as cytokine-based therapies such as…View ↗
Loading...
